Unique clinical presentations and follow-up outcomes from experience with congenital disorders of glycosylation: PMM2-PGM1-DPAGT1-MPI-POMT2-B3GALNT2-DPM1-SRD5A3-CDG
Author:
Yoldas Celik Merve1ORCID, Yazici Havva1ORCID, Erdem Fehime1, Yuksel Yanbolu Ayse1, Aykut Ayca2, Durmaz Asude2, Zeybek Selcan3, Canda Ebru1, Kalkan Ucar Sema1ORCID, Coker Mahmut1
Affiliation:
1. Department of Pediatrics, Division of Pediatric Metabolism and Nutrition , Ege University Faculty of Medicine , Izmir , Türkiye 2. Department of Genetics , Ege University Faculty of Medicine , Izmir , Türkiye 3. Department of Genetics , Tinaztepe University Faculty of Medicine , Izmir , Türkiye
Abstract
Abstract
Objectives
Congenital Glycosylation Disorders (CDG) are a large group of inherited metabolic diseases with multi-organ involvement. Herein, we aimed to expand the clinical characteristics of patients with CDG based on our experience with diagnoses and follow-up of CDG patients from different subtypes.
Methods
The clinical and laboratory findings from the last 15 years were reviewed retrospectively in Ege University Child Metabolism and Nutrition Department.
Results
There were 8 (57.2 %) females and 6 (42.8 %) males. Diagnoses of the patients were PMM2-CDG (n=4), PGM1-CDG (n=2), DPAGT1-CDG (n=2), SRD5A3-CDG (n=2), MPI-CDG (n=1), POMT2-CDG (n=1), B3GALNT2-CDG (n=1), DPM1-CDG (n=1). The clinical findings of the patients were dysmorphia (85.7 %), developmental delay (85.7 %), intellectual disability (85.7 %), ocular abnormalities (64.2 %), skeletal malformations (64.2 %), failure to thrive (57.1 %), microcephaly (57.1 %), hepatomegaly (35.7 %), hearing loss (35.7 %), seizures (28.5 %), gastrointestinal symptoms (21.4 %), endocrine abnormalities (21.4 %), and cardiac abnormalities (7.1 %). Laboratory findings were abnormal TIEF (92.8 %), abnormal liver enzymes (64.2 %), decreased protein C (64.2 %), decreased antithrombin III (64.2 %), decreased protein S (42.8 %), hypogammaglobulinemia (35.7 %), cerebellar hypoplasia (28.5 %), CK elevation (7.1 %), and hypoglycemia (7.1 %).
Conclusions
This study contributes to the literature by sharing our ultra-rare DPM1-CDG case with less than 20 cases in the literature and expanding the clinical and molecular characteristics of other CDG patients. Hyperinsulinemic hypoglycemia, short stature, hypothyroidism, growth hormone deficiency, hypogammaglobulinemia, pericardial effusion, elevated CK, congenital myasthenia, and anorectal malformation were unique findings that were observed. Cerebello-ocular findings accompanying multi-organ involvement were an essential clue for a possible CDG.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health
Reference43 articles.
1. Jaeken, J, Vanderschueren-Lodeweyckx, M, Casaer, P, Snoeck, L, Corbeel, L, Eggermont, E, et al.. Familial psychomotor retardation with markedly fluctuating serum prolactin, FSH and GH levels, partial TBG-deficiency, increased serum arylsulphatase A and increased CSF protein: a new syndrome?: 90. Pediatr Res 1980;14:179. https://doi.org/10.1203/00006450-198002000-00117. 2. Péanne, R, De Lonlay, P, Foulquier, F, Kornak, U, Lefeber, DJ, Morava, E, et al.. Congenital disorders of glycosylation (CDG): Quo vadis? Eur J Med Genet 2018;61:643–63. https://doi.org/10.1016/j.ejmg.2017.10.012. 3. Jaeken, J, Hennet, T, Matthijs, G, Freeze, HH. CDG nomenclature: time for a change. Biochimica Biophysica Acta 2009;1792:825–6. https://doi.org/10.1016/j.bbadis.2009.08.005. 4. Ondruskova, N, Cechova, A, Hansikova, H, Honzik, T, Jaeken, J. Congenital disorders of glycosylation: still “hot” in 2020. Biochimica Biophysica Acta (BBA) – General Subj 2021;1865:129751. https://doi.org/10.1016/j.bbagen.2020.129751. 5. Pérez-Cerdá, C, Girós, ML, Serrano, M, Ecay, MJ, Gort, L, Dueñas, BP, et al.. A population-based study on congenital disorders of protein N-and combined with O-glycosylation experience in clinical and genetic diagnosis. J Pediatr 2017;183:170–7. https://doi.org/10.1016/j.jpeds.2016.12.060.
|
|